|
 |
|
|
INO is receiving buzz from the investment community. |
|
|
Released on Sunday, February 12, 2012, 1:30 AM ET
Pittsburgh, PA (SpeculatingStocks) - Inovio Pharmaceuticals, Inc. (AMEX:INO) has been receiving attention lately from the message boards around the Internet. INO is working towards a "universal" influenza vaccine.
INO's novel SynCon® technology enables the Company to design synthetic vaccines with the potential to protect against unmatched sub-types and strains of pathogens, including newly emergent, unknown strains of a virus that will periodically emerge through mutation, as in the case of influenza.
INO is trading at a market cap of around $84 million. As of Sept. 30, 2011, INO had cash, cash equivalents and short term investments of approximately $31 million and no long-term debt. INO has a solid balance sheet with current assets exceeding current liabilities by over 3 to 1.
INO is off its recent short-term high and could be ready to go on its next leg higher. It is flu season and a stock like this could see even more attention than it has already seen.
The company's CEO is presenting an overview of the company at the 14th Annual BIO CEO and Investor Conference this Monday, 13th.
Find more stocks on the SpeculatingStocks homepage.
Comments:
|
|
